Downgrade: Here's How This Analyst Sees Beijing Balance Medical Technology Co.,Ltd. (SHSE:688198) Performing In The Near Term
Downgrade: Here's How This Analyst Sees Beijing Balance Medical Technology Co.,Ltd. (SHSE:688198) Performing In The Near Term
The latest analyst coverage could presage a bad day for Beijing Balance Medical Technology Co.,Ltd. (SHSE:688198), with the covering analyst making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with the analyst seeing grey clouds on the horizon.
分析师的最新报道可能预示着北京百伦医疗科技有限公司将迎来糟糕的一天。, Ltd.（SHSE: 688198），封面分析师全面下调了法定预算，这可能会让股东感到震惊。收入和每股收益（EPS）的预测均向下修正，分析师认为灰云即将出现。
Following the downgrade, the most recent consensus for Beijing Balance Medical TechnologyLtd from its lone analyst is for revenues of CN¥513m in 2024 which, if met, would be a substantial 34% increase on its sales over the past 12 months. Statutory earnings per share are presumed to jump 44% to CN¥1.18. Previously, the analyst had been modelling revenues of CN¥571m and earnings per share (EPS) of CN¥1.35 in 2024. Indeed, we can see that the analyst is a lot more bearish about Beijing Balance Medical TechnologyLtd's prospects, administering a measurable cut to revenue estimates and slashing their EPS estimates to boot.
评级下调后，其唯一分析师对北京百伦医疗科技有限公司的最新共识是，2024年的收入为5.13亿元人民币，如果得到满足，其销售额将比过去12个月大幅增长34％。据推测，每股法定收益将增长44％，至1.18元人民币。此前，该分析师一直在模拟2024年的收入为5.71亿元人民币，每股收益（EPS）为1.35元人民币。事实上，我们可以看出，分析师对北京百伦医疗科技有限公司的前景更加悲观，他大幅削减了收入预期，并下调了每股收益预期。
The consensus price target fell 8.0% to CN¥138, with the weaker earnings outlook clearly leading analyst valuation estimates.
共识目标股价下跌8.0％，至138元人民币，疲软的盈利前景显然领先于分析师的估值预期。
These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Beijing Balance Medical TechnologyLtd's past performance and to peers in the same industry. The analyst is definitely expecting Beijing Balance Medical TechnologyLtd's growth to accelerate, with the forecast 34% annualised growth to the end of 2024 ranking favourably alongside historical growth of 18% per annum over the past three years. Compare this with other companies in the same industry, which are forecast to grow their revenue 20% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analyst also expect Beijing Balance Medical TechnologyLtd to grow faster than the wider industry.
这些估计很有趣，但是在查看预测与北京百伦医疗科技有限公司过去的表现以及与同一行业的同行进行比较时，可以更粗略地描述一些细节。这位分析师肯定预计，北京百伦医疗科技有限公司的增长将加速，预计到2024年底的年化增长率为34％，而过去三年的历史年增长率为18％。相比之下，同行业的其他公司预计收入每年将增长20％。显而易见，尽管增长前景比最近更加光明，但分析师还预计，北京百伦医疗科技有限公司的增长速度将超过整个行业。
The Bottom Line
底线
The most important thing to take away is that the analyst cut their earnings per share estimates, expecting a clear decline in business conditions. While the analyst did downgrade their revenue estimates, these forecasts still imply revenues will perform better than the wider market. After such a stark change in sentiment from the analyst, we'd understand if readers now felt a bit wary of Beijing Balance Medical TechnologyLtd.
要了解的最重要的一点是，分析师下调了每股收益预期，预计业务状况将明显下降。尽管分析师确实下调了收入预期，但这些预测仍然意味着收入表现将好于整个市场。在分析师的情绪发生了如此明显的变化之后，我们可以理解读者现在是否对北京百伦医疗科技有限公司感到有些警惕。
Worse yet, our risk analysis suggests that Beijing Balance Medical TechnologyLtd may find it hard to maintain its dividend following these downgrades. What makes us say that? Learn more by visiting our risks dashboard on our platform here.
更糟糕的是，我们的风险分析表明，在这些下调评级之后，北京百伦医疗科技有限公司可能很难维持其股息。是什么让我们这么说？在此处访问我们平台上的风险控制面板，了解更多信息。
Of course, seeing company management invest large sums of money in a stock can be just as useful as knowing whether analysts are downgrading their estimates. So you may also wish to search this free list of stocks that insiders are buying.
当然，看到公司管理层将大量资金投资于股票与了解分析师是否在下调预期一样有用。因此，您可能还希望搜索这份内部人士正在购买的免费股票清单。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗？对内容感到担忧？直接联系我们。 或者，给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论，我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议，也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意，我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之，华尔街没有持有任何上述股票的头寸。
译文内容由第三方软件翻译。